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Take Home Message 
Mean mid-expiratory flow indicates early disease, worse health status and predicts decline in 
AATD patients without COPD. 
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Abstract 
Pathological studies suggest loss of small airways precedes airflow obstruction and 
emphysema in COPD. Not all Alpha 1 Anti-trypsin deficiency(AATD) patients develop 
COPD and measures of small airways function might be able to detect those at risk. 
 
MMEF, FEV1, FEV1/FVC ratio, health status, presence of emphysema (CT densitometry) 
and subsequent decline in FEV1 were assessed in 196 AATD patients.  
 
FEV1/FVC, FEV1 %predicted and lung densitometry, related to MMEF %predicted 
(r2=0·778, p<0·0001; r2 =0·787, p<0·0001, r2 =0·594, p<0·0001, respectively) in a curvilinear 
fashion.   Patients could be divided into those with normal FEV1/FVC and maximal mid-
expiratory flow (MMEF)(Group 1), normal FEV1/FVC and reduced MMEF(Group 2) and 
those with spirometrically-defined COPD(Group 3).  Patients in Group 2 had worse health 
status than Group 1 (Total SGRQ (median) 23·15 [IQR7·09-39·63] versus 9·67 [IQR 1·83-
22·35]; p=0·006) and had a greater subsequent decline in FEV1 (median change in FEV1=-
1·09% predicted/year [IQR=-1·91--0·04] versus -0·04%predicted/year [IQR =-0·67-0·03]; 
p=0·007). 
 
A reduction in MMEF is an early feature of lung disease in AATD and is associated with 
impaired health status and a faster decline in FEV1. 
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Introduction 
The early detection and prevention of COPD are key objectives both scientifically and 
clinically. COPD is defined physiologically by the presence of airflow obstruction 
(FEV1/FVC ratio<70%) and disease severity is stratified by FEV1 impairment
(1), however, 
there is increasing recognition that FEV1 and FEV1/FVC ratio lack sensitivity to identify 
early disease or patients at risk of subsequent decline without serial testing over a prolonged 
period of time(2, 3).  Therefore, there has been a revival of interest in assessing the small 
airways of the lungs. The cross-sectional micro-Computed Tomographic (CT) imaging 
studies of Hogg and colleagues(4, 5) reported major loss of small airways prior to the 
development of abnormal spirometry or emphysema in COPD patients. They hypothesised 
that reduced small airways function (by narrowing and reduction in number) precedes the 
decline in FEV1 and the development of emphysema in the very early stages of COPD.   This 
is important as emphysema can be present with normal spirometry(6, 7), is a predictor of 
mortality even in patients without COPD(8) and also relates to the subsequent decline in 
FEV1
(9, 10), which itself is a major predictor of mortality for COPD patients(11) and may not be 
influenced by current inhaled therapies(12). 
Understanding the relationship of small airways dysfunction (SAD) to the presence and 
subsequent progression of lung disease may be of central importance in the early detection of 
COPD. However, only a proportion of smokers develop COPD(13) and only a proportion of 
patients with COPD develop emphysema(14) and so studying an unselected, “at risk” 
population to determine the relationship between SAD and the subsequent onset of 
emphysema and COPD would be demanding as a proof of principle study.  Here, alpha-1 
antitrypsin deficiency (AATD) serves as a useful model. AATD is a genetic susceptibility to 
COPD, where a significant proportion of smokers develop COPD at a younger age than non-
AATD COPD, characterised by a predominant emphysema phenotype(15).  
Importantly a proportion of AATD patients who have never smoked also develop airflow 
obstruction and emphysema, although some do not(16) and currently we are unable to predict 
those at risk of decline.  Family testing identifies siblings/progeny earlier in the disease 
process, often before COPD and emphysema are detectable, allowing the whole time course 
of the disease process to be observed. 
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We hypothesised that a proportion of never smoking AATD patients would have evidence of 
SAD without COPD, and those patients would experience more lung symptoms and would be 
at greater risk of subsequent progression.  
The current study aimed to determine the relationship of the maximal mid-expiratory flow 
(MMEF- a spirometric parameter that when reduced is suggestive of SAD(17) and is readily 
available from the flow volume loop) to FEV1 and FEV1/FVC ratio, health status and CT 
defined emphysema. Of particular interest were subjects with both an FEV1 and FEV1/FVC 
ratio within the “normal range” to determine whether the presence of SAD might precede 
conventional airflow obstruction. In addition, follow up spirometry was analysed to relate the 
initial presence of SAD to subsequent decline in FEV1.  Percent predicted values were 
utilised as these are already adjusted for age, sex, height and ethnicity; thus accounting for 
these major determinants of lung function.  In this proof of principle study, only never 
smoking AATD patients were included to determine the natural history of this disease and 
avoid the potential impact of variable smoking histories on lung physiology. 
 
Materials and Methods 
 
Study Subjects 
ADAPT includes the UK registry for individuals with AATD. The programme was approved 
by the South Birmingham Research and Ethics Committee (Ref number; 3359a) and all 
patients provided written, informed consent. Patients were recruited either through medical 
referral (index) or family screening (non-index). For this study,  >95% of index patients were 
screened for AATD due to a past medical history of respiratory symptoms, including an 
awareness of breathlessness greater than expected, cough or recurrent chest infections.  Less 
than 5% of patients were identified by the presence of abnormal and unexplained liver 
function tests but not liver disease.  Patients with significant structural lung disease (such as 
bronchiectasis) were excluded.  Asthma is known to effect small airways function(18) and this 
was specifically screened for symptomatically as previously described(19).   
 
Patients participating in this study had annual assessments that included post-bronchodilator 
full lung function, blood biochemistry and haematology, and health status using the St. 
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George’s Respiratory Questionnaire (SGRQ). Patients also had a high resolution CT scan at 
baseline for qualitative and quantitative assessment where this had not been undertaken by 
the referring clinicians. 
 
Methods 
Initial baseline data was collected for lifelong never-smokers with a PiZZ AATD genotype. 
Measures of lung function were assessed on the same day as the clinical and health status 
data.  Spirometry data included FEV1, FEV1/FVC and MMEF. FEV1 and MMEF were 
expressed as % predicted to differentiate between natural decline in lung function due to 
ageing (where absolute values decrease but % predicted remains stable) and decline due to 
disease (where both absolute and % predicted values decrease). The FEV1/FVC ratio was 
expressed as a percentage and the gas transfer coefficient (Kco) was documented as % 
predicted.  
 
MMEF was chosen as it is the most readily accessible spirometric parameter that may relate 
to small airways function. However, the utility of MMEF in this carefully selected group of 
AATD patients is unclear.  In the current study a cut-off of 80% predicted was pragmatically 
chosen for MMEF as this is compatible with previous studies (for example,(20, 21)) and meant 
that those described as “normal” for the purposes of this study were less likely to include 
patients with small airways dysfunction.   
 
Decline in lung function was primarily determined by the change in % predicted for age, sex, 
height, and ethnicity using linear regression determined for all annual data points (provided 
≥4) for each patient. Rapid decliners were defined as those whose lung function decline 
(FEV1 change) was > −1.0% predicted per year as described previously
(22). 
 
All lung function tests were performed on Jaeger Masterscreen Pro lung function system 
(Jaeger Ltd, Hochberg, Germany) according to the Association for Respiratory Technology 
and Physiology/British Thoracic Society guidelines for quality control(23). Predicted values 
for all tests were calculated from the European Community for Steel and Coal reference 
equations(24). 
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For high resolution CT scans (GE Prospeed Scanner; General Electrical Medical Systems; 
Milwaukee, WI), 1 mm slices were taken at 10 mm intervals through the thorax at full 
inspiration. Mean lung density was recorded in Hounsfield Units (HU), with a value less than 
-950 HU used as a threshold consistent with the presence of macroscopic emphysema(25). CT 
data was included only where it was available and suitable for quantifiable analysis at the 
start of the study (at the time of baseline MMEF and lung function data) and is expressed as 
the PD15 (percentile point indicating the density of the lowest 15% of the voxels).   
 
Analysis 
The main outcome measures included the spirometric parameters FEV1, FEV1/FVC and 
MMEF. Secondary outcome measures included Kco and lung densitometry. T-tests,  Mann-
Whitney U tests and Kruskal Wallis were used to compare categories and spline modelling 
was used to determine the strength of any relationship. Chi-Squared tests were used to 
compare categorical data between groups. The predicted positive and negative value of 
MMEF to detect a rapid decline in lung function in patients with no physiological evidence of 
COPD was calculated using standard methods(26). A p value of <0·05 was taken to be 
statistically significant for all analyses.  
 
Results 
A total of 196 never-smoking PiZZ AATD patients were identified and divided into three 
physiological groups; Group 1 (n=43) had FEV1/FVC>70% and MMEF>80% predicted (no 
SAD, no COPD); Group 2 (n=40) had FEV1/FVC>70% and MMEF<80% predicted (SAD 
but no COPD) and Group 3 (n=113) had FEV1/FVC<70%, thus meeting physiological 
diagnostic criteria for COPD(27). No patients had an MMEF>80% predicted and evidence of 
COPD. Demographic data and lung function of patients in the three physiological groups are 
shown in Table 1.  There were a greater proportion of females in Group 2 (SAD but no 
COPD) compared to Group 1 (no SAD and no COPD, p=0·035) and Group 3 (COPD, 
p=0·002).  The average age increased across groups with Group 1 patients being the youngest  
(p<0·001 for the difference across all groups). There was a greater proportion of index 
patients in Group 3 compared to Group 1 (p<0·001) and Group 2 (p<0·001).  The prevalance 
of asthma was approximately 10% across this population and there were no differences in 
prevalence between groups (see table 1).   
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 Group 2 (SAD, no COPD) had worse lung function than Group 1 (no SAD, no COPD), 
including FEV1% predicted (p=0·011), FEV1/FVC (p=0·009), Kco% predicted (p=0·055) 
and, by definition, MMEF% predicted (p<0·001). In turn, Group 3 (COPD) had worse lung 
function than Group 2 (p<0·001 for all indices, including FEV1% predicted, FEV1/FVC, Kco 
% predicted and MMEF % predicted). 
 
Table 1 – Demographic Data 
Variables Group 1 Group 2 Group 3 
Number of Patients 43 40 113 
Males : Females 20 : 23 10 : 30  ǂ ¥ 60 : 53 
Age (yr) 38·1 ± 13·1 49·1 ± 13·1  ǂ 60·4 ± 9·4  ǂ§ 
Index : Non-Index 20 : 23 21 : 19 96 : 17  ǂ§  
FEV1 % Predicted 118·7 ± 13·7 105·6 ± 15·6 ǂ 65·0 ± 23·7  ǂ§ 
FVC (%) 
114.8  
(107.4 – 129.3) 
109.8 
(99.4 – 126.9) 
117.9 
(100.4 – 135.0) 
FEV1/FVC (%) 86·0 ± 5·7 79·2 ± 5·5 ǂ 44·6 ± 12·7  ǂ§ 
MMEF % Predicted 110·7 ± 19·7 60·1 ± 12·6  ǂ 17·5 ± 11·4  ǂ§ 
Kco % Predicted 93·4 ± 18·5 83·5 ± 15·5 67·3 ± 20·7  ǂ§ 
∆ FEV1 (ml/yr) 
-27.9¥ § 
(-49.1 - -4.87) 
-52.7 ǂ 
(-78.5 - -22.7) 
-57.3 ǂ 
(-83.3 - -27.3) 
Serum AATD level 
4.4 
(3.05 – 4.98) 
3.9 
(2.8 – 4.6) 
4.2 
(3.28 – 5.03) 
Asthma, n (%) 4 (9.3) 4 (10) 5 (4.4) 
 
Patient demographics are summarised for the 3 groups with mean ± SD unless otherwise stated. Change in FEV1 is the 
decline based on 4 measurements taken over 3 years and expressed as median and range. AAT level is serum level (measured 
in umol/l and is given as the median and range. Asthma is the number in each group with a Consultant physician confirmed 
diagnosis. Differences between groups are indicated by the symbols; ǂ Significantly different from Group 1: § Significantly 
different from Group 2:¥ Significantly different from Group 3 
 
Relationship between lung function measurements 
There was a strong (r2=0·778, p<0·0001) relationship between the FEV1/FVC ratio and 
MMEF % predicted (Figure 1) and for FEV1 % predicted and MMEF % predicted (r
2=0·787, 
p<0·0001).  There was a weaker though significant relationship (r2=0·198, p<0·0001) 
between Kco % predicted and MMEF % predicted.  
 
 
Health Status 
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Health status was assessed at baseline using the SGRQ.  The median total SGRQ score was 
greater (indicating worse health status) in Group 2 (SAD, no COPD: median 23·15, IQR 
7·09-39·63) than Group 1 (no SAD, no COPD: median 9·67, IQR 1·83-22·35, p=0·006) 
(Figure 2A). The same trend was seen for the individual domains with a median of 29·49, 
IQR 5·96-51·00 and 5·84, IQR 0·00-26·97, respectively for activity (p<0·001) (Figure 2B) 
and 15·38, IQR 1·90-26·40 and 3·89, IQR 0·00-11·60, respectively for disease impact 
(p=0·028) (Figure 2C). However, there was no significant difference (p>0·05) between 
SGRQ symptom scores for Group 1 (median 29·17, IQR 5·23-45·61) and Group 2 (median 
37·77, IQR 17·07-59·59) (Figure 2D). SGRQ scores were even greater in Group 3 (COPD) 
compare to Group 2 for total score (median 38·25, IQR 27·06-53·72, p<0·0001), activity 
(median 53·62, IQR 35·60-66·19, p<0·0001), disease impact (median 24·80, IQR 14·11-
40·50, p<0·001)) and symptoms (median 54·74, IQR 42·38-68·57, p=0·002). 
 
 
Lung Function Decline 
The rate of FEV1 decline (% predicted) following baseline measurement was measured over 
at least 3 years to ensure at 4 or more data points for analysis(16). The median decline was 
greater in Group 2 (SAD, no COPD: median change in FEV1 -1·09% predicted/year, IQR -
1·91 to -0·04) than Group 1 (no SAD, no COPD: median change in FEV1 -0·04% 
predicted/year, IQR -0·67 to 0·03) (p=0·007). The median decline in FEV1 in Group 3 
(COPD) was similar (p>0·05) to that in Group 2 (-1·41% predicted/year, IQR -2·27 to -0·22) 
as shown in Figure 3.The decline in FEV1 expressed as ml/year is shown in Table 1. 
85% of AATD patients without COPD and an MMEF >80% predicted did not subsequently 
decline rapidly (an 85% negative predictive value).  The positive predictive value was 57%.  
 
CT Densitometry 
Quantitative CT densitometry was available for 109 patients.  There was a significant 
relationship of mean lung density in Hounsfield Units (HU) to MMEF % predicted (Figure 4) 
(r2=0·594, p<0·0001).   Although numbers are low, all patients with MMEF > 80% predicted 
had no evidence of emphysema (n = 3, Median PD15 (Interquartile range, IQR) -904.6 (-
922.76 - -876.75).  11 patients had a reduced MMEF (<80% predicted) with the PD15 above 
the -950 HU threshold (median PD15 (IQR); -902.8(-913.05 - -873.35), with no macroscopic 
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emphysema. 95 patients had macroscopic emphysema (determined as the PD15 <-950HU, 
Median PD15 (IQR) -957.93 (-968-63—942.22) and all of these had severely reduced MMEF 
(≤20% predicted).  
 
Discussion 
The current paper describes unique data from a cohort of never-smoking individuals with 
AATD who have never received augmentation therapy, showing that subjects without 
spirometric evidence of COPD include some with reduced values for MMEF (defined here as 
<80% predicted), potentially suggestive of impaired small airways function. Those with an 
MMEF <80% predicted already have evidence of reduced health status despite their FEV1 
and FVC being within the normal range and subsequently demonstrated a more rapid decline 
in FEV1.  
 
MMEF appears of questionable value in an unselected population(28), but the usefulness of a 
spirometric parameter maybe different in different populations. The subjects included in the 
present work are never smoking AATD PiZZ patients, a highly selected population, and these 
data suggest MMEF may be useful to identify subgroups in this cohort with specific 
characteristics and to predict disease progression. 
  
Differences in the shape of the forced expiration curve have been noted as early as 1976, 
where a “kink” in the spirogram was associated with a higher prevalence of emphysema in 
patients with airflow obstruction(29) and lower maximal expiratory flow measurements at 
75%, 50% and 25% of FVC were seen in PiMZ AATD non-smokers compared to PiMM 
patients(30). Since this time there has been little further information about small airways 
function in AATD although a recent study demonstrated an overall trend for more rapid 
decline in MMEF in PiMZ individuals over 11 years compared to those with the PiMM and 
PiMS phenotypes, whilst FEV1 and FEV1/FVC declined at the same rate in all groups 
(although values were expressed as absolute change and not % predicted)(31).  Studies of small 
airway function in non AATD COPD are also limited. Gold 0 COPD patients (those with a 
normal FEV1/FVC but considered “at risk”) had lower MMEF %predicted than normal 
subjects(32). In addition, MMEF/FVC has been used as a diagnostic parameter for early stage 
COPD in smokers with otherwise normal spirometry(33). Collectively, these studies support 
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the concept that MMEF may be useful in detecting early pathological changes in COPD and 
support our findings in AATD.  However the utility of MMEF or other potential measures of 
small airways function would also need to be assessed in a non-AATD COPD cohort and 
patients at risk of COPD to determine more generalised utility. 
 
What constitutes an abnormal MMEF is uncertain. The normal range for MMEF based on 
standardised residuals/z-scores is broad (34) and in a general population reporting MMEF 
using z-scores is not clinically useful over and above the traditional spirometric parameters 
such as FEV1/FVC
(28). In the current study a cut-off of 80% predicted was pragmatically 
chosen for MMEF as this is compatible with previous studies (for example,(20, 21)) but patterns 
were similar if a cut off of 75% or 70% predicted were chosen. Moreover, choosing an 80% 
predicted cut-off for MMEF means that a greater number of patients with SAD are likely to 
be included in Group 2. The 70% fixed FEV1/FVC ratio definition of COPD was also chosen 
to align this paper with the current GOLD strategy and enable easier comparison with other 
published work in this area. 
 
The average age of the patients studied here ranged from 40 years for those in Group 1 to 50 
years for those with MMEF values suggestive of SAD (Group 2) and 60 for those with COPD 
(Group 3). Lung function data, however, is presented as % predicted (therby accounting for 
age differences) and thus the decline in lung function could relate to the early stages of 
airway remodelling in Group 2 that precede more significant airflow limitation associated 
with COPD (Group 3).  There was also a trend towards lower gas transfer in Group 2, which 
may reflect early emphysematous change.  Patients in Group 2 (SAD, no COPD) also had 
impairment of health status compared to those with higher MMEF (Group 1). Although this 
may be at variance with earlier work in AATD that used a different symptom 
questionnaire(35) it is consistent with more recent work that has shown patients with GOLD 
Stage 0 COPD(27) can also have reduced quality of life(36). The presence of worse symptoms 
in patients with mild spirometric COPD has also been shown in our previous work(37) and, 
collectively, the data in the current study supports a subtle decline in health status in tandem 
with early deterioration in lung physiology. Prospective studies would be needed to confirm 
this. 
 
The predictive value of MMEF in this study suggests it may be an effective screening tool to 
select those most at risk of a fast decline in this group of patients. If this were confirmed in 
Page 21 of 36 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
prospective studies, these tests might identify a physiological subgroup (with evidence of 
SAD) that require closer monitoring, and perhaps earlier interventions when considering 
suitability for future therapeutic trials (such as alpha-1 antitrypsin augmentation).   There are 
other tests of small airways function but MMEF was chosen in this proof of principle study as 
it is readily available in most physiology centres.  Prospective studies might identify even 
more informative measures. 
 
From a pathophysiological viewpoint, the data provide support for the cross-sectional studies 
of Hogg and colleagues(4). Observational studies of lung specimens from patients with COPD 
(10 of whom had features typical of AATD—panlobular emphysema ,younger and lower 
smoking history) and emphysema has highlighted major loss of small airways in the absence 
of emphysema, leading to the hypothesis that this is a precursor of alveolar destruction. 
Currently, pathological changes cannot be studied prospectively but the physiological data 
presented here is consistent with this concept. A proportion of our patients underwent 
quantitative CT scan density analysis at baseline and there was a relationship to MMEF 
values. Density relationships to the presence of emphysema have been studied extensively in 
the past and the best data compared to pathological specimens remains that by Gevenois and 
his colleagues(38) who determined that a threshold of -950HU showed the best correlation 
with emphysema. Our data was analysed as the PD15 which is used in most modern 
publications and reflects the threshold of the least dense 15% of voxels. It is therefore not 
entirely comparable with the pathological threshold described by Gevenois which indicated 
<7% of voxels below this threshold, but is similar to the values of <10%(39) and <13%(40) 
found in normal subjects,  and all subjects with PD15 below this threshold in our study had 
marked impairment of MMEF. Importantly, there was a significant proportion of patients 
with reduced MMEF who had a PD15 well above this threshold, suggesting the presence of 
SAD without emphysema. As patients with AATD who develop COPD almost invariably 
have emphysema, the data suggest significant loss of and/or impairment of airflow in the 
small airways does occur before emphysema becomes apparent. The age difference between 
our physiological groups also supports this as a natural temporal progression pathologically 
and confirms the importance to express values as % predicted in such studies. However, it 
should be noted that not all patients with AATD develop COPD and emphysema(25) and early 
evidence of SAD may differentiate these diverse outcomes. Our current data reflects an 
average result for the whole lung rather than regional assessment of the upper and lower 
zones which may more closely reflect different distribution patterns of emphysema known to 
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have different physiological effects especially in established disease(41). This would be 
important for definitive interpretation in future prospective studies of AATD patients without 
COPD  
 
Apart from age and lung function, the only other clear differences between the groups were 
sex in Group 2 (with a higher percentage of females having an MMEF <80% predicted 
without COPD) and a higher percentage of non-index cases in Groups 1 and 2. Index status is 
to be expected, since family screening tends to identify patients with more preserved lung 
function than found in index cases(42). It is unclear why more females were present in Group 
2 than Group 1 or 3.  There is no published literature to suggest AATD females experience a 
faster decline than men.  While this could reflect sampling bias, this observation requires 
follow up to determine its significance. Other studies have also looked at sex and respiratory 
symptoms, small airways responses and hyper-responsiveness and there are conflicting 
results (for example,(43, 44)); this subject appears far less understood and far more complex 
than initially thought but we have utilised percent predicted results in our analysis as these 
take into consideration sex and height differences in lung function to try and overcome the 
inherent size difference in the lungs of our patients. 
 
The current study has excluded current or ex-smokers, which is both a strength and a 
weakness. Studying never smokers allows the natural history of AATD alone to be defined as 
smoking accelerates the development of COPD in AATD and a faster pathological 
progression. In addition most individuals stop smoking on diagnosis of AATD thereby 
altering the natural history.  Our current cohort of over 900 AATD subjects and the group 
with normal spirometry includes no active smokers and only 21 ex-smokers; too small a 
proportion to analyse meaningfully. This study does not include information of passive 
smoke exposure or occupational history.  While both factors may affect small airways 
function and lung development in childhood in some patients with AATD, the main question 
addressed here is whether current evidence of small airways dysfunction might impact on 
health status or subsequent FEV1 decline in this population. Thus whatever the preceding 
time course involved, tests consistent with SAD act as a marker of faster subsequent decline. 
 
MMEF is affected by loss of elastic recoil (seen in emphysema), which results in expiratory 
airflow limitation due to dynamic airways compression. However, we have shown that a 
number of patients have severely reduced MMEF but no evidence of emphysema on CT scan. 
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We suggest that this could reflect small airways dysfunction but interpretation without 
pathology will require a more comprehensive long term study. 
 
In summary, the implications of our findings in AATD are two-fold. First, we now have 
physiological evidence to support the previous histological studies that SAD is an early 
feature of lung disease in AATD and precedes the development of emphysema and COPD(5). 
MMEF % predicted may be a useful marker of early disease in these patients.  
Second, AATD patients with a reduced MMEF appear more likely to be “rapid decliners”(16) 
than those with preserved small airway function. Therefore, MMEF may be a more sensitive 
physiological marker of AATD patients at risk of decline than FEV1/FVC. There are also 
potential implications in non AATD-COPD, where re-evaluation of MMEF% predicted may 
provide a screening tool to identify patients at risk of developing emphysema and COPD 
prior to changes in FEV1 and FEV1/FVC ratio. 
 
Figure legends 
FIGURE 1.  
FEV1/FVC ratio is plotted against MMEF % predicted. Each point represents data from a 
single patient (n=196) with all measurements taken on the same day. Groups 1, 2 and 3 are 
highlighted. 
 
FIGURE 2.  
The charts show median, IQR and minimum/maximum bars for total SGRQ scores (A) and 
individual domain scores for activity (B), disease impact (C) and symptoms (D) for Groups 1, 
2 and 3. P values are shown for each comparison. 
 
FIGURE 3.  
The chart shows median, IQR and minimum/maximum bars in the annual change in FEV1 
(expressed as % predicted) for Groups 1, 2 and 3. Values were calculated from the regression 
line of annual serial measurements of 4 data points or more. A lower value indicates a faster 
rate of decline. The median FEV1 percent predicted decline in Group 1 was approximately 
zero, suggesting these patients experienced an FEV1 decline in keeping with that expected 
with age alone.  Patients within Groups 2 and 3 experienced a decline in FEV1 greater than 
seen with age alone, suggesting disease progression.  
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FIGURE 4.  
The chart shows mean lung density (HU) versus MMEF % predicted. Each point represents 
data from a single patient (n=109). Patients with reduced MMEF (<80% predicted) but a lung 
density above that typical of macroscopic emphysema (>950 HU) are shown by the shaded 
area. 
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FIGURE 1.  
FEV1/FVC ratio is plotted against MMEF % predicted. Each point represents data from a single patient 
(n=196) with all measurements taken on the same day. Groups 1, 2 and 3 are highlighted.  
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FIGURE 2.  
The charts show median, IQR and minimum/maximum bars for total SGRQ scores (A) and individual domain 
scores for activity (B), disease impact (C) and symptoms (D) for Groups 1, 2 and 3. P values are shown for 
each comparison.  
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As for figure 2A  
 
104x143mm (96 x 96 DPI)  
 
 
Page 32 of 36European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
 
 
As for figure 2A  
 
104x143mm (96 x 96 DPI)  
 
 
Page 33 of 36 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
 
 
As for figure 2A  
 
104x143mm (96 x 96 DPI)  
 
 
Page 34 of 36European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
 
 
FIGURE 3.  
The chart shows median, IQR and minimum/maximum bars in the annual change in FEV1 (expressed as % 
predicted) for Groups 1, 2 and 3. Values were calculated from the regression line of annual serial 
measurements of 4 data points or more. A lower value indicates a faster rate of decline. The median FEV1 
percent predicted decline in Group 1 was approximately zero, suggesting these patients experienced an 
FEV1 decline in keeping with that expected with age alone.  Patients within Groups 2 and 3 experienced a 
decline in FEV1 greater than seen with age alone, suggesting disease progression.  
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FIGURE 4.  
The chart shows mean lung density (HU) versus MMEF % predicted. Each point represents data from a 
single patient (n=109). Patients with reduced MMEF (<80% predicted) but a lung density above that typical 
of macroscopic emphysema (>950 HU) are shown by the shaded area.  
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